{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:21:34Z","timestamp":1789410094454,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T00:00:00Z","timestamp":1299024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s11940-011-0119-8","type":"journal-article","created":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T01:10:57Z","timestamp":1299028257000},"page":"311-323","source":"Crossref","is-referenced-by-count":50,"title":["Immunotherapy of Inflammatory Myopathies: Practical Approach and Future Prospects"],"prefix":"10.1007","volume":"13","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,2]]},"reference":[{"key":"119_CR1","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325:1487\u201398.","journal-title":"N Engl J Med"},{"key":"119_CR2","volume-title":"Myology, 1335\u20131383","author":"AG Engel","year":"2006","unstructured":"Engel AG, Hohlfeld R, Banker BQ. Polymyositis and dermatomyositis. In: Engel A, editor. Myology, 1335\u20131383. 3rd ed. New York: McGraw-Hill; 2006.","edition":"3"},{"key":"119_CR3","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10:346\u201352. This is an up-to-date, balanced review on inflammatory myopathies.","DOI":"10.1016\/j.coph.2010.03.001"},{"key":"119_CR4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0889-857X(02)00021-2","volume":"28","author":"FL Mastaglia","year":"2002","unstructured":"Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am. 2002;28:723\u201341.","journal-title":"Rheum Dis Clin North Am"},{"key":"119_CR5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971\u201382.","journal-title":"Lancet"},{"key":"119_CR6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/CBO9780511674747.026","volume-title":"Disorders of voluntary muscle","author":"MC Dalakas","year":"2010","unstructured":"Dalakas MC, Karpati G. The inflammatory myopathies. In: Karpati G, Hilton-Jones D, Bushby K, Griggs RC, editors. Disorders of voluntary muscle. 8th ed. Cambridge: Cambridge University Press; 2010. p. 427\u201352.","edition":"8"},{"key":"119_CR7","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Sporadic inclusion body myositis\u2014diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006;2437\u201347.","DOI":"10.1038\/ncpneuro0261"},{"key":"119_CR8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1474-4422(07)70171-0","volume":"6","author":"M Needham","year":"2007","unstructured":"Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 2007;6:620\u201331.","journal-title":"Lancet Neurol"},{"key":"119_CR9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38:705\u201313.","journal-title":"Ann Neurol"},{"key":"119_CR10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1750-3639.2009.00290.x","volume":"19","author":"V Askanas","year":"2009","unstructured":"Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol. 2009;19:493\u2013506.","journal-title":"Brain Pathol"},{"key":"119_CR11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncprheum0140","volume":"2","author":"MC Dalakas","year":"2006","unstructured":"Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006;2:219\u201327.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"119_CR12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","volume":"314","author":"JT Kissel","year":"1986","unstructured":"Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314:329\u201334.","journal-title":"N Engl J Med"},{"key":"119_CR13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2005.05.003","volume":"26","author":"H Wiendl","year":"2005","unstructured":"Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 2005;26:373\u201380.","journal-title":"Trends Immunol"},{"key":"119_CR14","unstructured":"Dalakas MC. An update on inflammatory and autoimmune myopathies. Neuropath Appl Neurobiol. 2010 Dec 14 (Epub ahead of print). This is a recent review on the diagnosis and immunopathology of PM, DM, IBM and NAM."},{"key":"119_CR15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.410230111","volume":"23","author":"G Karpati","year":"1988","unstructured":"Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol. 1988;23:64\u201372.","journal-title":"Ann Neurol"},{"key":"119_CR16","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1172\/JCI118749","volume":"97","author":"N Goebels","year":"1996","unstructured":"Goebels N, Michaelis D, Engelhardt M, et al. Differential expression of perforin in muscle-infiltrating T cell in polymyositis and dermatomyositis. J Clin Invest. 1996;97:2905.","journal-title":"J Clin Invest"},{"key":"119_CR17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0165-5728(03)00255-8","volume":"142","author":"P Confalonieri","year":"2003","unstructured":"Confalonieri P, Oliva L, Andreetta F, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol. 2003;142:130\u20136.","journal-title":"J Neuroimmunol"},{"key":"119_CR18","first-page":"702","volume":"17","author":"AG Engel","year":"1986","unstructured":"Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol. 1986;17:702\u201321.","journal-title":"Hum Pathol"},{"key":"119_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/mus.20649","volume":"35","author":"SA Greenberg","year":"2007","unstructured":"Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve. 2007;35:17\u201323.","journal-title":"Muscle Nerve"},{"key":"119_CR20","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/WNL.58.12.1779","volume":"58","author":"JL Bleecker De","year":"2002","unstructured":"De Bleecker JL, De Paepe B, Vanwalleghem IE, Schr\u00f6der JM. Differential expression of chemokines in inflammatory myopathies. Neurology. 2002;58:1779\u201385.","journal-title":"Neurology"},{"key":"119_CR21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mus.10462","volume":"28","author":"D Figarella-Branger","year":"2003","unstructured":"Figarella-Branger D, Civate M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve. 2003;28:659\u201382.","journal-title":"Muscle Nerve"},{"key":"119_CR22","doi-asserted-by":"crossref","unstructured":"Mammen AL, Casciola-Rosen LA, Hall JC, et al. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 2009, 60(12):3784\u201393. This important study demonstrates that the autoantibody against chromatin remodeler Mi-2, which is present in some DM patients, is strongly immunolocalized in the perifascicular fibers and also in the regenerating muscle in vivo. The study confirms that the perifascicular atrophic fibers are indeed regenerating and that Mi-2 may play a role in myofiber stability during the regeneration process.","DOI":"10.1002\/art.24977"},{"key":"119_CR23","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6(3):129\u201337. This is an up-to-date, critical review of current therapies in myositis.","DOI":"10.1038\/nrrheum.2010.2"},{"issue":"2","key":"119_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2003-41136","volume":"23","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol. 2003;23(2):199\u2013206.","journal-title":"Semin Neurol"},{"issue":"3","key":"119_CR25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1756285608097463","volume":"1","author":"MC Dalakas","year":"2008","unstructured":"Dalakas MC. Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther Adv Neurol Disord. 2008;1(3):157\u201366.","journal-title":"Ther Adv Neurol Disord."},{"key":"119_CR26","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry. 2009;80(8):832\u20138. The various drugs, especially statins, that trigger myopathies are reviewed, and a differential diagnosis is provided.","DOI":"10.1136\/jnnp.2008.168294"},{"key":"119_CR27","doi-asserted-by":"crossref","unstructured":"Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418\u201324. This important study introduced the concept of PM\/IBM and demonstrated that up to 15% of patients with clinical features of IBM do not have vacuoles or amyloid deposits in their biopsy specimens.","DOI":"10.1212\/01.wnl.0000277527.69388.fe"},{"key":"119_CR28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/brain\/120.1.39","volume":"120","author":"G Blume","year":"1997","unstructured":"Blume G, Pestronk A, Frank B, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain. 1997;120:39\u201345.","journal-title":"Brain"},{"key":"119_CR29","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","volume":"326","author":"FW Miller","year":"1992","unstructured":"Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in patients with polymyositis and dermatomyositis. N Engl J Med. 1992;326:1380\u20134.","journal-title":"N Engl J Med"},{"key":"119_CR30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<651::AID-MUS1>3.0.CO;2-7","volume":"20","author":"FL Mastaglia","year":"1997","unstructured":"Mastaglia FL, Phillips BA, Zilko PJ. Treatment of inflammatory myopathies. Muscle Nerve. 1997;20:651\u201364.","journal-title":"Muscle Nerve"},{"key":"119_CR31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00002281-199411000-00008","volume":"6","author":"MC Dalakas","year":"1994","unstructured":"Dalakas MC. Current treatment of the inflammatory myopathies. Curr Opin Rheumatol. 1994;6:595\u2013601.","journal-title":"Curr Opin Rheumatol"},{"key":"119_CR32","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993\u20132000.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"119_CR33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2249.2009.04025.x","volume":"158","author":"RAC Hughes","year":"2009","unstructured":"Hughes RAC, Dalakas MC, Cornblath DR, et al. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol. 2009;158 Suppl 1:34\u201342.","journal-title":"Clin Exp. Immunol"},{"key":"119_CR34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","volume":"65","author":"FL Mastaglia","year":"1998","unstructured":"Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1998;65:107\u201310.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Spec No 2","key":"119_CR35","first-page":"9","volume":"29","author":"P Ch\u00e9rin","year":"2008","unstructured":"Ch\u00e9rin P. Current therapy for polymyositis and dermatomyositis. Rev M\u00e9d Interne. 2008;29(Spec No 2):9\u201314.","journal-title":"Rev M\u00e9d Interne"},{"issue":"19","key":"119_CR36","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367\u201375.","journal-title":"JAMA"},{"issue":"10","key":"119_CR37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","volume":"4","author":"MC Dalakas","year":"2008","unstructured":"Dalakas MC. B cells as a therapeutic target in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4(10):557\u201367.","journal-title":"Nat Clin Pract Neurol"},{"key":"119_CR38","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD. Rituximab in the treatment of dermatomyositis: an open label pilot study. Arthritis Rheum. 2005;52:601\u20137.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"119_CR39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143(6):763\u20137.","journal-title":"Arch Dermatol"},{"key":"119_CR40","doi-asserted-by":"crossref","unstructured":"Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010;3(2):93\u2013105. This is an up-to-date review on the uses of rituximab in neurologic disorders.","DOI":"10.1177\/1756285609356135"},{"key":"119_CR41","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","volume":"353","author":"CV Oddis","year":"1999","unstructured":"Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762\u20133.","journal-title":"Lancet"},{"key":"119_CR42","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-control study. Neurology. 1997;48:712\u20136.","journal-title":"Neurology"},{"key":"119_CR43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2000","unstructured":"Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247:22\u20138.","journal-title":"J Neurol"},{"key":"119_CR44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","volume":"58","author":"P Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58:326.","journal-title":"Neurology"},{"key":"119_CR45","doi-asserted-by":"crossref","unstructured":"Schmidt J, Barthel K, Wrede A, et al. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008;131:1228\u201340. This important study demonstrates the interrelationship between inflammation and degeneration. Functional studies confirm that exposure of muscle cells to pro-inflammatory cytokines induces an overexpression of APP with subsequent accumulation of amyloid aggregates.","DOI":"10.1093\/brain\/awn053"},{"key":"119_CR46","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Interplay between inflammation and degeneration: using inclusion body myositis to study neuroinflammation. Ann Neurol. 2008;64:1\u20133. This critical editorial emphasizes the concept of neuroinflammation in IBM based on the cross-talk between inflammatory and degenerative molecules.","DOI":"10.1002\/ana.21452"},{"key":"119_CR47","doi-asserted-by":"crossref","unstructured":"Muth IE, Barthel K, B\u00e4hr M, et al. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 2009;80:1344\u20139. The authors convincingly demonstrate that \u03b1B-crystallin is, along with proinflammatory markers, an early event associated with cell stress-response that precedes accumulation of \u03b2-amyloid.","DOI":"10.1136\/jnnp.2009.174276"},{"key":"119_CR48","doi-asserted-by":"crossref","unstructured":"Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132:1536\u201344. This excellent clinicopathologic proof-of-principle study demonstrates that depletion of T cells from the periphery results in suppression of endomysial inflammation and some degeneration-associated molecules, along with short-term clinical stability. The study, although small and uncontrolled, is important because future antilymphocyte therapies may have an effect not only on inflammatory mediators but also in halting degeneration.","DOI":"10.1093\/brain\/awp104"},{"key":"119_CR49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ana.410390122","volume":"39","author":"JN Pruitt 2nd","year":"1996","unstructured":"Pruitt 2nd JN, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol. 1996;39:139\u201343.","journal-title":"Ann Neurol"},{"key":"119_CR50","doi-asserted-by":"crossref","unstructured":"vLayzer R, Lee HS, Iverson D, Margeta M. Dermatomyositis with inclusion body myositis pathology. Muscle Nerve. 2009;40(3):469\u201371. This single case report is significant because it presents a patient with DM with pathologic features of IBM, supporting the concept that intense inflammation may trigger the typical pathologic features of IBM and that early initiation of anti-inflammatory therapy may arrest progression to clinical IBM.","DOI":"10.1002\/mus.21377"},{"key":"119_CR51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nmd.2005.12.008","volume":"16","author":"MC Dalakas","year":"2006","unstructured":"Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord. 2006;16:223\u201336.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"119_CR52","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.nurt.2008.08.008","volume":"5","author":"H Wiendl","year":"2008","unstructured":"Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics. 2008;5(4):548\u201357.","journal-title":"Neurotherapeutics"},{"key":"119_CR53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-41139","volume":"23","author":"R Hohlfeld","year":"2003","unstructured":"Hohlfeld R, Dalakas MC. Basic principles of immunotherapy in neurological diseases. Semin Neurol. 2003;23:121\u201332.","journal-title":"Semin Neurol"},{"key":"119_CR54","first-page":"2080","volume":"35","author":"B Thomson","year":"2008","unstructured":"Thomson B, Corris P, Miller JAL, Cooper RG. Alemtuzumab (Campath) in the treatment of refractory polynyositis. J Rheumatol. 2008;35:2080\u20131.","journal-title":"J Rheumatol"},{"key":"119_CR55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","volume":"50","author":"GJ Hengstman","year":"2003","unstructured":"Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: preliminary observations. Eur Neurol. 2003;50:10\u20135.","journal-title":"Eur Neurol"},{"key":"119_CR56","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","volume":"43","author":"I Labioche","year":"2004","unstructured":"Labioche I, Liozon E, Weschler B, et al. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford). 2004;43:531\u20132.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0119-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-011-0119-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0119-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T17:23:27Z","timestamp":1637342607000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-011-0119-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,2]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["119"],"URL":"https:\/\/doi.org\/10.1007\/s11940-011-0119-8","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,2]]}}}